CardioNext®
No-charge genetic testing for Danon disease and suspected inherited cardiomyopathy via Ambry's 92-gene CardioNext panel, sponsored by Rocket Pharmaceuticals.
Accessed through the Mission: Genome Sponsored Testing Program•Sponsored by Rocket Pharma•Performed by Ambry Genetics
Designed to support clinical decision-making and ordering in your practice.
For healthcare providers
Overview
Mission: Genome is a Rocket Pharma-sponsored testing program performed by Ambry Genetics that provides CardioNext, a 92-gene panel covering inherited cardiomyopathies, arrhythmias, and related cardiovascular conditions, along with genetic counseling. No cost is passed to the patient, the ordering provider, or any payer, including government payers. Given the genetic and phenotypic overlap among inherited cardiomyopathies, the comprehensive panel offers an efficient path to molecular confirmation or identification of at-risk individuals in a population where early diagnosis directly impacts clinical management.
When to consider this test
Patient selection
- Patient must reside in the United States.
- Patient is 40 years of age or younger
- Provider has a high clinical suspicion for an inherited cardiomyopathy
- Patient meets at least one of the following:
- Documented family history of Danon disease
- Cardiomyopathy diagnosis not attributable to acquired etiologies (e.g., medications, viral myocarditis)
Workflow
How to use this program
- 1
Identify eligible patients
Consider patients with suspected or confirmed ARVC, concerning arrhythmias, or relevant family history.
- 2
Order through your usual workflow
Use your standard ordering process for submitting tests to Example Genetics Lab (portal or existing workflows).
- 3
Integrate results into management
Use results to refine diagnosis, guide cascade testing, and inform monitoring and treatment decisions.
- 4
Plan follow-up and cascade testing
Determine downstream actions including surveillance, family member testing, and long-term management plans.
Billing overview
Program billing
For eligible patients, the sponsor has arrangements with the laboratory that may reduce or cover some or all of the patient's out-of-pocket cost. Actual cost and patient responsibility vary by program criteria. Refer to lab or sponsor materials for details.
Quality & privacy
Laboratory quality & data handling
Testing is performed by Ambry Genetics, a CLIA-certified laboratory (CLIA 05D0981414). Your sample is processed using validated methods and quality controls to support reliable genetic results.
Your health information is handled under privacy and security practices that are intended to align with applicable regulations. For program- and lab-specific details, review the privacy information provided by the laboratory and sponsor.
FAQ
Frequently asked questions
Which patients are appropriate for the Mission: Genome Danon disease testing program?
The Mission: Genome Danon Disease program is designed for patients in the United States under 40 years of age with high clinical suspicion of an inherited cardiomyopathy. Patients must meet the program's eligibility criteria, which your Ambry Genetics representative can review with you. The program targets individuals for whom early molecular diagnosis could meaningfully influence surveillance and management decisions.
What does the Mission: Genome CardioNext panel cover for inherited cardiomyopathy and Danon disease?
The Mission: Genome program utilizes Ambry Genetics' CardioNext panel, a 92-gene panel that includes LAMP2 and covers inherited cardiomyopathies, arrhythmias, and other inherited cardiovascular conditions. The comprehensive scope accounts for the significant genetic and clinical overlap among these phenotypes, making it an effective tool for both confirming a suspected diagnosis and identifying alternative genetic etiologies.
What specimen types are accepted and how do I order a kit for the Mission: Genome Danon disease program?
The Mission: Genome program accepts blood, saliva, or buccal specimens. Kits can be requested online through Ambry Genetics' provider portal by selecting the 'Mission Genome - Rocket' TRF type, or a paper-based Test Requisition Form can be downloaded and included with the specimen. A custom ordering form ships with each kit. Kits and all materials are provided at no cost.
What is the turnaround time for Mission: Genome Danon disease genetic testing results?
Results from the Mission: Genome Danon Disease program are typically available two to three weeks after Ambry Genetics receives the specimen. The ordering provider receives a notification when results are ready for review.
Is there any cost or prescribing obligation when ordering through the Mission: Genome Danon disease program?
There is no cost and no prescribing or purchase obligation associated with ordering through the Mission: Genome Danon Disease Genetic Testing Program. Rocket Pharma sponsors the program and covers all testing and counseling costs. No patients, providers, or payers, including government payers, are billed. Ordering is purely a diagnostic decision with no strings attached.
Does the Mission: Genome Danon disease program include genetic counseling support?
Yes, the Mission: Genome Danon Disease program includes access to genetic counseling as part of the sponsored offering. This support is available to help patients and families interpret results and understand implications for clinical management and family screening. The counseling is fully covered by the program at no cost to the patient or provider.
Which patients are eligible for Mission: Genome Danon Disease genetic testing?
Patients may qualify for Mission: Genome if they meet the program's eligibility criteria:
- Patient must reside in the United States.
- Patient is 40 years of age or younger
- Provider has a high clinical suspicion for an inherited cardiomyopathy
- Patient meets at least one of the following:
- Documented family history of Danon disease
- Cardiomyopathy diagnosis not attributable to acquired etiologies (e.g., medications, viral myocarditis)
See an issue with this program?